Events
Jenny Speck to Speak on BARBRI Webinar
Partner Jenny Speck will speak on BARBRI’s live video CLE program, “Tax Credit Insurance for Energy Projects: PFE Exclusions, Recapture, …
November 19, 2026
November 19, 2026 • 1-minute read
Insight
Client Alerts
January 22, 2026 • 9-minute read
On January 12, 2026, the Delaware Supreme Court issued an en banc opinion in Johnson & Johnson v. Fortis Advisors LLC, No. 490, 2024, 2026 WL 89452 (Del. Jan. 12, 2026), largely affirming and reversing in part a Court of Chancery post-trial decision that awarded former stockholders of Auris Health, Inc. (“Auris”) over $1 billion in damages in their post-closing earnout dispute against Johnson & Johnson (“J&J”). Apart from the high stakes, the Supreme Court’s unanimous opinion, authored by Justice LeGrow, is notable because it is the first opinion to address the recent slew of earnout disputes in Delaware (which we have previously summarized here). The decision reinforces three key principles of Delaware M&A and contract law. First, absent unusual circumstances, a court will not utilize the implied covenant of good faith and fair dealing to rewrite the parties’ agreement as reflected in the words in the contract. Second, where a party’s obligation is dependent on regulatory approval, courts will hold the parties to the standard they set for themselves in the contract, including where that standard is by reference to the buyer’s past practices with respect to securing regulatory approval for its own products. Third, fraud claims based on extracontractual statements are precluded only by clear “anti-reliance” language in the contract, not by an “exclusive remedy” provision. Together, these principles underscore the importance of careful drafting so that the language of an agreement conforms to the parties’ expectations.
In its quest to expand into the surgical robotics market, J&J, a global healthcare company, pursued a transaction with Auris—a medical robotics company known for its two flagship robotic-assisted surgical devices (“RASDs”), Monarch and iPlatform, which had yet to receive certain FDA approvals. In February 2019, the parties entered into a merger agreement whereby J&J would acquire Auris for $3.4 billion in cash. Because much of Auris’s value derived from future regulatory approval and commercial performance of its RASDs, J&J agreed to also pay Auris’s stockholders up to $2.35 billion in cash based on ten incremental milestones set forth in the Merger Agreement to be achieved at certain post-closing intervals between 2020–2024.
The Merger Agreement included a provision requiring J&J to use “commercially reasonable efforts” to achieve the milestones consistent with its normal practice for its own “priority medical device products” (the “Efforts Provision”). The Merger Agreement also included a one-way anti-reliance provision whereby J&J, but not Auris, expressly disclaimed reliance on statements made outside of the agreement. It also provided that the agreement’s indemnification provisions were the exclusive remedy for claims made after closing related to the acquisition, except “in the case of fraud by [the parties] with respect to making the representations and warranties in [the Merger] Agreement” (the “Exclusive Remedy Provision”).
Following closing, J&J’s handling of iPlatform allegedly diverged from what the Merger Agreement contemplated. Within weeks, J&J launched an initiative referred to as “Project Manhattan” whereby J&J supposedly pitted iPlatform against its comparable product, Verb, in a “winner-take-all showdown” in which the “loser would likely ‘cease to exist.’” Despite winning the duel, iPlatform was then combined into a single project with Verb, which, among other things, relegated iPlatform to the role of a “parts shop for Verb.” In addition, according to plaintiffs, J&J shifted away from the agreed-upon “MVP” strategy, which set out to achieve the first milestone by obtaining regulatory approval for simple surgical procedures and incrementally progress to more complex procedures to achieve later milestones. Instead, J&J pursued a new strategy to immediately develop “a full-featured, commercially attractive system that was better able to compete head-to-head” with market-leading systems. Doing so allegedly made achieving regulatory approval, and thus the related milestones, more difficult. Around the same time, the FDA changed its regulatory pathway for iPlatform, switching from the 510(k) pathway to a pathway requiring “De Novo” review.1 Since the Merger Agreement specifically pegged J&J’s first milestone for iPlatform to 510(k) approval, J&J treated the FDA’s regulatory shift as excusing its obligations to achieve all the subsequent iPlatform milestones on the notion that each were dependent on J&J achieving the first milestone—which, given the regulatory shift, “could not be satisfied as written.” Following this regulatory shift, J&J revised the employee incentive program and eliminated awards for achieving certain regulatory milestones defined in the Merger Agreement. Ultimately, J&J concluded that “iPlatform would not be viable in a commercially reasonable timeframe,” and according to the Supreme Court, “effectively shelved the iPlatform program.” Monarch, for its part, remained on the market but did not meet its milestones by the contractual deadlines. With no milestones met, none of the $2.35 billion in earnouts was paid.
Fortis Advisors LLC, as a representative for Auris stockholders under the Merger Agreement, sued J&J in the Court of Chancery, claiming, inter alia, that J&J (1) breached the Merger Agreement’s Efforts Provision and the implied covenant of good faith and fair dealing, and (2) fraudulently induced Auris to accept a contingent payment instead of additional upfront consideration for one of the Monarch-related milestones. Despite the post-closing regulatory change requiring a different “De Novo” review of iPlatform by the FDA—which J&J argued excused its obligations to achieve the first milestone and each of the subsequent iPlatform milestones—the Court of Chancery held that J&J breached the Merger Agreement by failing to devote the contractually required level of effort with respect to the iPlatform milestones. It reasoned that the implied covenant of good faith and fair dealing required J&J to pursue the alternate pathway for iPlatform’s first regulatory milestone and to treat that approval as the functional equivalent of the regulatory clearance specified in the contract. As for Monarch, the court also found that J&J, through its CEO, fraudulently induced Auris to accept a $100 million payment contingent on one of the Monarch milestones—which would be achieved following regulatory approval for robotically driven lung tissue ablation using J&J’s NeuWave FLEX catheter—by portraying it as “essentially certain” while omitting a recent patient death during a study involving FLEX and resulting FDA investigation which J&J knew would threaten timely approval. The court entered judgment for Fortis in excess of $1 billion in contract and fraud damages, plus pre-judgment interest.
1 In the 510(k) pathway, a manufacturer seeks clearance by showing that a new device is substantially equivalent to a legally marketed predicate device; this route has historically been the fastest and least burdensome path to approval. The De Novo pathway, by contrast, is intended for novel devices that lack an appropriate predicate; this pathway typically requires more extensive data and a longer review.
This information is provided by Vinson & Elkins LLP for educational and informational purposes only and is not intended, nor should it be construed, as legal advice.
Discover our latest:
Events
Jenny Speck to Speak on BARBRI Webinar
Partner Jenny Speck will speak on BARBRI’s live video CLE program, “Tax Credit Insurance for Energy Projects: PFE Exclusions, Recapture, …
November 19, 2026
November 19, 2026 • 1-minute read
Events
Kathy Pakenham and Adriana Wirtz to Speak at TEI’s IRS Roundtable
Partners Kathy Pakenham and Adriana Wirtz will examine how a leaner, more data-driven IRS is selecting and conducting large business …
November 19, 2026
November 19, 2026 • 1-minute read
Client Alerts
Single v Multi Contracts in Nuclear Projects: The Size of the Burden
Introduction The construction of nuclear energy projects is complex and capital-intensive, and the contracting structure can significantly affect project delivery, …
November 13, 2026
November 13, 2026 • 6-minute read
Articles
State Attorneys General Widen the Antitrust Battlefield
State attorneys general are moving to the center of antitrust enforcement, with bipartisan coalitions attacking merger settlements, information-sharing arrangements, labor-market …
November 13, 2026
November 13, 2026 • 4-minute read
Events
Jenny Speck to Speak at Lockton U.S. Energy Risk Summit
Partner Jenny Speck will speak at Lockton’s U.S. Energy Risk Summit on November 12, 2026, in Houston, Texas. The summit …
November 12, 2026
November 12, 2026 • 1-minute read
Thoughts or questions? Send us a note, and we’ll connect you with the right person.